Annonce préalable: Les résultats de l'année 2003 du groupe Novartis

If approved, Cosentyx® (secukinumab) will become the only IL-17A inhibitor for adolescents with moderate to severe HS in Europe1,2HS affects as many as one in 100 people worldwide,3 with more than...

RemIND data show clinically meaningful responses through Week 52 across three most prevalent CIndU subtypes, including after switching from placebo at Week 241Twice as many Rhapsido-treated patients...